C2 PHARMA’S Upcoming Launch of Oxybuprocaine Hydrochloride

C2 Pharma is excited to announce the upcoming launch of their new Ophthalmic API, Oxybuprocaine Hydrochloride. To learn more check out the full press release.

 C2 PHARMA,  the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), is excited to announce the upcoming launch of their new API, Oxybuprocaine HCL, an API that will be manufactured by our manufacturing partner Laurus Labs. We are completing the validation process, by April 2024, and upon completion, GMP samples will be available to our customers worldwide for evaluation and testing.

We expect to submit a Certificate of Suitability (CEP) by May 2024, a US-Drug Master File (US-DMF) by August 2024, and a Certificate of Acceptance of Drugs and Food (CADIFA) in Q4 of 2024.

The addition of this API will extend our range of high-quality Ophthalmic APIs and strengthen our commitment to meeting the market's evolving needs.